Why the study?
The article aims to provide an overview of general pharmacology, supporting evidence, and current status of intravenous antiplatelet therapies (GPIs and cangrelor), focusing on contemporary clinical indications.
This review summarizes the pharmacology and contemporary clinical indications for intravenous antiplatelet therapies, highlighting cangrelor's rapid anti-ischemic benefit without increased major bleeding during PCI.
Answers are grounded in this paper and cite their sources.
Supports cangrelor consideration in PCI; leaves open optimal integration pending prospective trials.
receptor antagonist. In a large-scale regulatory trial, cangrelor administration during PCI allowed for rapid, potent and rapidly reversible inhibition of platelet aggregation, with an anti-ischemic benefit and no increase in major bleeding. This article aims to provide an overview of general pharmacology, supporting evidence and current status of intravenous antiplatelet therapies (GPIs and cangrelor), with a focus on contemporary indications for their clinical use.
No takes yet. Share an insight, caveat, or question.
Capodanno et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: